You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Under the deal, the companies aim to develop a companion diagnostic for Bayer's solid tumor drug larotrectinib for the Chinese market.
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.
The European Commission will now consider whether to grant marketing authorization to the drug regimen.
Under the agreement, AstraZeneca will be able to use ImaginAb's CD8 ImmunoPET technology in its clinical trials in North America and Europe.
A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways.
Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.
Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.
Despite the availability of more personalized options, the market dynamics are getting more complex and oncologists need education and tools to keep up with advances.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
The newly formed company will focus on building out a precision cancer therapy-based portfolio from existing and new product candidates.